EGFR and non-small cell lung carcinoma: Alternatively, in the Indian cohort of 325 patients with NSCLC, the rate of EGFR mutation reached 45.8%, and ALK rearrangements were found in 11.4% of cases, however, KRAS mutations were present in only 10.2% (33).